Cirius Therapeutics Expands Scientific Advisory Board

June 13, 2019 – Cirius Therapeutics announced today that Daniel Bloomfield M.D., will be joining Cirius’ scientific advisory board.

Read On ›

Interim Data on Cirius Therapeutics’ MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions

June 5, 2019 - Cirius Therapeutics announced today that results from an interim analysis of exploratory endpoints from its Phase 2bEMMINENCE trial of MSDC-0602K will be presented at the American Diabetes Association 79 Scientific Sessions.

Read On ›

Cirius Therapeutics Adds to Leadership Team

June 3, 2019 – Cirius Therapeutics announced today that Andrew Knudten, M.B.A., will join the company as chief technical officer and will be responsible for advancing the company’s manufacturing and supply chain operations.

Read On ›

Cirius Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton

January 4, 2019 - Cirius Therapeutics announced today that Dennis Fenton, Ph.D. has been appointed to the company’s board of directors as an independent member.

Read On ›

Cirius Therapeutics Expands Board of Directors with Appointment of Elaine D. Sun

December 13, 2018 – Cirius Therapeutics announced today that Elaine D. Sun, M.B.A., has been appointed to the company’s board of directors as an independent director.

Read On ›

Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis

October 25, 2018 - Cirius Therapeutics today announced positive results from an interim analysis of exploratory endpoints from its ongoing, fully enrolled Phase 2b clinical trial (the EMMINENCE trial) evaluating MSDC-0602K in 402 patients diagnosed with […]

Read On ›

Cirius Therapeutics Completes $40 Million Series A Financing to Fund Phase 2b Study of MSDC-0602K in NASH, Adds to Executive Team

SAN DIEGO and KALAMAZOO, Mich., April 11, 2017 /PRNewswire/ – Cirius Therapeutics, previously known as Octeta Therapeutics, announced today the completion of a Series A financing of up to $40 million led by Frazier Healthcare Partners […]

Read On ›